DYKDDDDK (a C- or N-terminal tag)

YPYDVPDYA

On page 67, lines 27-30:

A vector for the cloning of the generated PCR product encompassing the expression cassette for native human blood coagulation factor VII was prepared by cloning the intron from pCINeo (Promega). The synthetic intron from pCI-Neo was amplified using standard PCR conditions as described above and the primers: (SEQ ID NOS 5-6, respectively).

On page 68, lines 14-20:

For example, in order to change the codons for R315 and V317 to the codons for N315 and T317 the following primers were used pair vice for the primary PCR's: (SEQ ID NOS 7-8, respectively)

CBProFpr216: 5'-CTTAAGGATCCCGCCACCATGGTCAGCCAG-3' and

CBProFpr229: 5'-GGAGTCCCCGGTTTTGTTGGACTGCTGC-3',

and (SEQ ID NOS 9-10, respectively)

CBProFpr221: 5'-ACTTAAGCTTTTATCAAGGGA-3' and

CBProFpr228: 5'-GCAGCAGTCCAACAAAACCGGGGACTCC-3'.

On page 68, lines 26-29:

Furthermore, in cases where the introduced mutation(s) were sufficiently close to a unique restriction endo-nuclease site in the expression plasmid variant genes were constructed using construction procedure encompassing a single PCR step and a subsequent cloning. For instance, the substitution K143N+N145T was introduced by use of the PCR primers: (SEQ ID NOS 11 & 9, respectively)

REMARKS

A complete replacement sequence listing is submitted in both paper and electronic format, as well as a marked copy of the relevant portion of the specification.

CONCLUSION

If the Examiner believes a telephone conference would expedite prosecution of this application, please telephone the undersigned at 510-337-7871.

LAW OFFICES OF
JONATHAN ALAN QUINE
P.O. BOX 458
Alameda, CA 94501
(510) 337-7871
Fax (510) 337-7877

Respectfully submitted,



Jonathan Alan Quine
Reg. No. 41,261

MARKED COPY OF RELEVANT PORTION OF THE SPECIFICATION FOR USSN 09/782,587

Insertions are indicated by underlining of the character.

Page 45, lines 7-20:

The identity of the specific tag to be used is not critical as long as the tag is capable of being expressed with the polypeptide and is capable of being immobilised on a suitable surface or carrier material. A number of suitable tags are commercially available, e.g., from Unizyme Laboratories, Denmark. For instance, the tag can consist of any of the following sequences: (SEQ ID NOS 12-16, respectively)

His-His-His-His-His-His

Met-Lys-His-His-His-His-His-His

Met-Lys-His-His-Ala-His-His-Gln-His-His

Met-Lys-His-Gln-His-Gln-His-Gln-His-Gln-His-Gln-His-Gln

Met-Lys-His-Gln-His-Gln-His-Gln-His-Gln-His-Gln-His-Gln-Gln

or any of the following: (SEQ ID NOS 17-19, respectively)

EQKLI SEEDL (a C-terminal tag described in Mol. Cell. Biol. 5:3610-16, 1985)

DYKDDDDK (a C- or N-terminal tag)

YPYDVPDYA

On page 67, lines 27-30:

A vector for the cloning of the generated PCR product encompassing the expression cassette for native human blood coagulation factor VII was prepared by cloning the intron from pCINeo (Promega). The synthetic intron from pCI-Neo was amplified using standard PCR conditions as described above and the primers: (SEQ ID NOS 5-6, respectively).

On page 68, lines 14-20:

For example, in order to change the codons for R315 and V317 to the codons for N315 and T317 the following primers were used pair vice for the primary PCR's: (SEQ ID NOS 7-8, respectively)

CBProFpr216: 5'-CTTAAGGATCCCGCCACCATGGTCAGCCAG-3' and

CBProFpr229: 5'-GGAGTCCCCGGTTTTGTTGGACTGCTGC-3',

and (SEQ ID NOS 9-10, respectively)

CBProFpr221: 5'-ACTTAAGCTTTTATCAAGGGA-3' and

CBProFpr228: 5'-GCAGCAGTCCAACAAAACCGGGGACTCC-3'.

On page 68, lines 26-29:

Furthermore, in cases where the introduced mutation(s) were sufficiently close to a unique restriction endo-nuclease site in the expression plasmid variant genes were constructed using construction procedure encompassing a single PCR step and a subsequent cloning. For instance, the substitution K143N+N145T was introduced by use of the PCR primers: (SEQ ID NOS 11 & 9, respectively)